285 studies found for:    "Breast cancer male"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting An Observational Registry-Based Study of a Potential Link Between Finasteride (MK-0906) and Male Breast Cancer in 4 Nordic Countries (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention: Drug: Finasteride
2 Recruiting A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
4 Active, not recruiting Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Conditions: Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: tipifarnib;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: pegfilgrastim;   Procedure: conventional surgery;   Procedure: axillary lymph node dissection
5 Recruiting Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: eribulin mesylate;   Other: laboratory biomarker analysis
6 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
7 Recruiting Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysis
8 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
9 Suspended Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
10 Completed Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
Conditions: Central Nervous System Metastases;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
11 Recruiting Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Estrogen Receptor-negative Breast Cancer;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HER2-negative Breast Cancer;   Intraocular Lymphoma;   Male Breast Cancer;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progesterone Receptor-negative Breast Cancer;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Breast Cancer;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Active, not recruiting Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: carboplatin
13 Active, not recruiting Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Completed
Has Results
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: saracatinib;   Other: laboratory biomarker analysis
15 Withdrawn Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
16 Active, not recruiting Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: immunologic technique;   Biological: synthetic tumor-associated peptide vaccine therapy
17 Active, not recruiting Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Biological: trastuzumab;   Drug: paclitaxel;   Other: laboratory biomarker analysis
18 Recruiting Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: veliparib;   Drug: cyclophosphamide;   Other: placebo;   Other: laboratory biomarker analysis
19 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Male Breast Cancer;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Peripheral T-cell Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Colon Cancer;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Rectal Cancer;   Stage I Small Lymphocytic Lymphoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Colon Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Breast Cancer;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Dietary Supplement: cholecalciferol;   Other: placebo;   Other: laboratory biomarker analysis
20 Recruiting FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Conditions: Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Device: positron emission tomography;   Device: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years